Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

insulin aspart, insulin aspart protamine drug combination 30:70

Known as: BIAsp 30, biphasic insulin aspart 30:70, biphasic insulin aspart 30 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
AIMS Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of IDeg and IAsp. This pan-Asian, 26-week trial… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
OBJECTIVE Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
AIMS The IMPROVE observational study evaluated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Insulin is recommended as a second-line treatment after diet and metformin fail to reach and/or maintain glycemic… Expand
  • table I
  • table III
  • table IV
  • figure 1
  • figure 2
Is this relevant?
2009
2009
Aim: This 3-month study compared the effect on overall glycemic control of adding biphasic insulin aspart 30 (BIAsp30) and… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
AIMS The IMPROVE study is a multinational, open-label, non-randomised, 26-week observational study assessing the safety and… Expand
Is this relevant?
2007
2007
BACKGROUND Modern premixed insulins offer a flexible approach to the initiation of insulin therapy in patients with poorly… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND: In this study, we sought to compare the long-term safety and efficacy of biphasic insulin aspart 30 (BIAsp30) with… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
OBJECTIVE Biphasic insulin aspart 30 (BIAsp30) is a dual release formulation, containing 30% soluble and 70% protamine… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
AbstractObjective: With the aim to obtain a premixed rapid-acting insulin with a serum insulin profile more closely resembling… Expand
Is this relevant?